Home » Topics » BioWorld Science

BioWorld Science
RSS

OsmoCyte approved for marketing in U.S.

Dec. 9, 1996

Medarex bispecific antibody enters phase II in colon cancer patients

Dec. 9, 1996

MGI Pharma acquires drugs from Ilex Oncology

Dec. 9, 1996

Another British Biotech compound reaches clinical stage

Dec. 9, 1996

Successful phase III results reported for British Biotech PAF antagonist

Dec. 9, 1996

British Biotech discontinues development of MMP inhibitor

Dec. 9, 1996

Dusa photodynamic therapy advances to phase III

Dec. 9, 1996

Access in-licenses polymer platinum compounds

Dec. 9, 1996

InSite Vision completes preliminary clinical trial of ophthalmic drug candidate

Dec. 9, 1996

Therapeutically active NPY analog reported by academic source

Dec. 9, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...